Rilonacept clinical trials
Also written KPL-914 and IL-1 Trap.
How each study uses rilonacept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rilonacept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Feb 2008 · ARCALYST · BLA 125249 (FDA, Drugs@FDA)
- European Union
- 23 Oct 2009 · Rilonacept Regeneron (previously Arcalyst) · EMEA/H/C/001047 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 14
Regeneron Pharmaceuticals (9) · Kiniksa Pharmaceuticals (UK), Ltd. (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (2) · Southern California Institute for Research and Education (1) · VA Office of Research and Development (1) · Boston University (1) · University of Colorado, Denver (1) · Montefiore Medical Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test rilonacept.
- Mar 2027Rilonacept in Subjects With Cardiac SarcoidosisPhase 2 · Mayo Clinic
Studies
Open first, then newest update. How each study uses rilonacept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Rilonacept in Subjects With Cardiac SarcoidosisRecruitingPhase 2Mayo ClinicNCT06660732Written as Rilonacept
- A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic HepatitisCompletedPhase 2Southern California Institute for Research and EducationNCT01903798Written as Rilonacept
- Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent PericarditisCompletedPhase 3Kiniksa Pharmaceuticals (UK), Ltd.NCT03737110Written as Rilonacept
- A Pilot Study of KPL-914 in Recurrent PericarditisCompletedPhase 2Kiniksa Pharmaceuticals (UK), Ltd.NCT03980522Written as KPL-914
- Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)CompletedPhase 2VA Office of Research and DevelopmentNCT00897715Written as Rilonacept
- IL1-TRAP, Rilonacept, in Systemic SclerosisCompletedPhase 1/2Boston UniversityNCT01538719Written as Rilonacept
- Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)CompletedPhase 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT01801449Written as Rilonacept
- Rilonacept for Treatment of Autoimmune Neurosensory Hearing LossStatus unknownEarly Phase 1Stanley CohenNCT02828033Written as Rilonacept
- Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout FlaresTerminatedPhase 3Regeneron PharmaceuticalsNCT01459796Written as Rilonacept
- Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout FlaresCompletedPhase 2Regeneron PharmaceuticalsNCT00610363Written as Rilonacept
- Study Utilizing Rilonacept in Gout ExacerbationsCompletedPhase 3Regeneron PharmaceuticalsNCT00855920Written as Rilonacept
- PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1CompletedPhase 3Regeneron PharmaceuticalsNCT00829829Written as Rilonacept 80 mg
- Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)CompletedPhase 3Regeneron PharmaceuticalsNCT00856206Written as Rilonacept
- PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)CompletedPhase 3Regeneron PharmaceuticalsNCT00958438Written as Rilonacept
- Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)CompletedPhase 4University of Colorado, DenverNCT01663103Written as Rilonacept
- Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young AdultsCompletedPhase 2Montefiore Medical CenterNCT00534495Written as Rilonacept
- Rilonacept (Arcalyst ®) in the Treatment of Subacromial BursitisCompletedNot applicableKeesler Air Force Base Medical CenterNCT01830699Written as Rilonacept
- Interleukin-1 Trap to Treat Autoinflammatory DiseasesCompletedPhase 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT00094900Written as IL-1 Trap
- Rilonacept in Diabetes Mellitus Type 1: Safety StudyCompletedPhase 1University of Texas Southwestern Medical CenterNCT00962026Written as Rilonacept
- Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedPhase 1Regeneron PharmaceuticalsNCT01803321Written as rilonacept (IL-1 Trap)
Codes
What other systems call rilonacept · ClinicalTrials.gg INT005322
- MeSH (NLM) C531377rilonaceptConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 8K80YB5GMGRILONACEPTConfirmed FDA, NLM, Wikidata
- RxNorm 763450Confirmed FDA, Wikidata
- Wikidata Q7334300rilonaceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84137RilonaceptOne source FDA
- DrugBank DB06372One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531377 | rilonacept | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 8K80YB5GMG | RILONACEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 763450 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7334300 | rilonacept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84137 | Rilonacept | One source FDA |
| DrugBank | DB06372 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.